Half-year report · HY
8129.TEDINET S100X3KF
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥767.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥1.52T | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥755.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥7.3bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥8.3bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥20.7bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.6bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥9.1bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥8.5bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥6.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥19.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥6.3bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥5.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥754.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥722.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥770.7bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥487.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥465.9bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥267.0bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥256.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥262.6bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥96.5bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥86.5bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥89.5bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥78.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥103.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥128.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥25.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥26.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥10.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥12.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥10.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥99.12 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥313.2 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.71 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥92.72 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥284.22 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥75.64 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 35.3% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥30.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥30.1bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥1.3bn |
| Dispensing Pharmacyreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥49.5bn |
| Dispensing Pharmacyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥49.5bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2m |
| Dispensing Pharmacyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥600m |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.7bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4.4bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥120m |
| Medical Products Retailreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥739.2bn |
| Medical Products Retailreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥714.2bn |
| Medical Products Retailreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥24.9bn |
| Medical Products Retailreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥7.3bn |
| Other Related Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.6bn |
| Other Related Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.8bn |
| Other Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥746m |
| Other Related Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥475m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥798.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥767.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥30.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥8.5bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥29.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥29.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.3bn |
| Dispensing Pharmacyreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥47.1bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥47.1bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥19m |
| Dispensing Pharmacyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥18m |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.4bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥442m |
| Medical Products Retailreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥728.7bn |
| Medical Products Retailreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥704.3bn |
| Medical Products Retailreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥24.4bn |
| Medical Products Retailreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥8.0bn |
| Other Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| Other Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| Other Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥994m |
| Other Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥203m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥784.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥755.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥29.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥8.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 586
| Item | Context | Value | Unit |
|---|---|---|---|
| Shareholding ratio | InterimInstant_No1MajorShareholdersMember | 0.1474 | |
| Number of shares held | InterimInstant_No2MajorShareholdersMember | 7060000 | |
| Shareholding ratio | InterimInstant_No2MajorShareholdersMember | 0.1079 | |
| Number of shares held | InterimInstant_No3MajorShareholdersMember | 3500000 | |
| Shareholding ratio | InterimInstant_No3MajorShareholdersMember | 0.0535 | |
| Number of shares held | InterimInstant_No4MajorShareholdersMember | 2400000 | |
| Shareholding ratio | InterimInstant_No4MajorShareholdersMember | 0.0367 | |
| Number of shares held | InterimInstant_No5MajorShareholdersMember | 1404000 | |
| Shareholding ratio | InterimInstant_No5MajorShareholdersMember | 0.0215 | |
| Number of shares held | InterimInstant_No6MajorShareholdersMember | 1350000 | |
| Shareholding ratio | InterimInstant_No6MajorShareholdersMember | 0.0206 | |
| Number of shares held | InterimInstant_No7MajorShareholdersMember | 1333000 | |
| Shareholding ratio | InterimInstant_No7MajorShareholdersMember | 0.0204 | |
| Number of shares held | InterimInstant_No8MajorShareholdersMember | 1328000 | |
| Shareholding ratio | InterimInstant_No8MajorShareholdersMember | 0.0203 | |
| Number of shares held | InterimInstant_No9MajorShareholdersMember | 1232000 | |
| Shareholding ratio | InterimInstant_No9MajorShareholdersMember | 0.0188 | |
| Number of shares held | InterimInstant_No10MajorShareholdersMember | 1137000 | |
| Shareholding ratio | InterimInstant_No10MajorShareholdersMember | 0.0174 | |
| Number of shares held | InterimInstant | 30393000 | |
| Shareholding ratio | InterimInstant | 0.4645 | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 7593200 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesReciprocalHoldingSharesWithFullVotingRightsTreasurySharesEtcMember | 33500 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 65345300 | |
| Number of voting rights issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 653453 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | 53942 | |
| Number of shares issued shares voting rights | InterimInstant | 73025942 | |
| Number of voting rights issued shares voting rights | InterimInstant | 653453 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row1Member | 7593200 | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row1Member | 7593200 | |
| Shareholding ratio treasury shares etc | InterimInstant_Row1Member | 0.1040 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row2Member | 33000 | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row2Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row2Member | 33000 | |
| Shareholding ratio treasury shares etc | InterimInstant_Row2Member | 0.0005 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row3Member | 500 | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row3Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row3Member | 500 | |
| Shareholding ratio treasury shares etc | InterimInstant_Row3Member | 0.0000 | |
| Number of shares held in own name treasury shares etc | InterimInstant | 7626700 | |
| Number of shares held in others names treasury shares etc | InterimInstant | － | |
| Total number of shares held treasury shares etc | InterimInstant | 7626700 | |
| Shareholding ratio treasury shares etc | InterimInstant | 0.1045 | |
| Cash and deposits | Prior1YearInstant | 86533000000 | JPY |
| Cash and deposits | InterimInstant | 96450000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |